Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2025
0mins
Should l Buy DXR?
Source: Newsfilter
WellStar Health System's Presentation: Dr. Brian Howard from WellStar Health System will present at the MedAxiom CV Transforum Spring'25 Conference, showcasing how their Advanced Heart Failure program has successfully reduced acute kidney injury rates following left ventricular assist device implantation through blood volume analysis (BVA).
Impact of BVA Technology: BVA-guided care has demonstrated significant improvements in patient outcomes, including reductions in mortality and readmissions, while providing clinicians with accurate data to optimize treatment plans and individualize care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXR
About DXR
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Daxor Corporation Reports 2025 Financial and Technological Advancements
- Strong Financial Performance: As of December 31, 2025, Daxor's net assets reached $45,887,266, reflecting a $10,094,965 increase from 2024, indicating robust growth potential in the blood volume measurement technology sector.
- Significant Revenue Growth: In 2025, Daxor's operating division reported a 45% increase in unaudited revenues year-over-year, primarily driven by sales of single-use blood volume diagnostic kits for heart failure management and military contracts, highlighting rapid market demand.
- FDA Approval of New Product: Daxor received FDA 510(k) clearance in August 2025 for its next-generation portable blood volume analyzer, which provides results three times faster than the previous system, significantly enhancing clinical fluid management efficiency.
- Strategic Restructuring and Enhanced Transparency: Daxor plans to transition its regulatory reporting framework from the Investment Company Act of 1940 back to the Securities Exchange Act of 1934, which is expected to simplify financial disclosures, boost investor confidence, and attract deeper institutional interest.
See More
Daxor Reports 45% Year-over-Year Revenue Growth
- Significant Revenue Growth: Daxor's unaudited operating revenues for FY 2025 increased by 45% year-over-year, indicating strong market demand and business expansion capabilities in the blood volume sector.
- Net Asset Value Increase: As of December 31, 2025, Daxor's total net assets reached $45,887,266, an increase of over $10 million from the prior year, reflecting effective asset management and enhanced investor confidence.
- Per-Share Value Growth: The net asset value per share rose to $9.07, representing a $1.82 increase compared to December 31, 2024, demonstrating the company's positive progress in enhancing shareholder value.
- Investment Activity Returns: Daxor recorded net realized gains of $745,334 from investment activities for the fiscal year and sold its remaining investment positions in December 2025 to focus entirely on its primary blood volume business, showcasing a strategic decision to concentrate resources.
See More
Geopolitical Crisis in the Middle East Impacts European Stocks
- Market Sentiment Decline: European stocks are expected to open lower due to the ongoing geopolitical crisis in the Middle East, with the UK's FTSE index projected to drop by 0.7%, Germany's DAX down 1%, France's CAC 40 down 0.75%, and Italy's FTSE MIB down 0.6%, reflecting investor concerns about market outlook.
- Oil Price Surge: Global crude oil prices surged on Monday amid fears that the escalating U.S.-Iran conflict could disrupt oil infrastructure and push fuel prices higher, thereby increasing inflationary risks and adding economic pressure.
- Increased Demand for Safe Havens: As uncertainty rises, demand for gold as a safe haven has surged, with global equities under pressure, particularly as U.S. futures and Asian markets fell on Tuesday, indicating a risk-averse sentiment among investors.
- Military Reinforcements and Uncertain Situation: The U.S. military is sending more forces to the region, with President Trump stating that the conflict could last four to five weeks but may extend longer, highlighting the complexity and uncertainty of the situation, while the EU calls for de-escalation and civilian protection.
See More
Trump's Global Tariff Policy Sparks Market Volatility
- Negative Market Reaction: European stocks are expected to open lower as Trump's announcement to raise global tariffs from 10% to 15% creates uncertainty, with the U.K.'s FTSE projected to drop 0.2%, Germany's DAX down 0.7%, France's CAC 40 down 0.4%, and Italy's FTSE MIB down 0.45%, indicating market unease.
- Tariff Policy Shift: Trump stated on social media that the new tariffs would be effective immediately and warned of potential additional levies, reflecting his hardline stance on trade policy, which could exacerbate global trade tensions.
- Increased Market Uncertainty: U.S. stock futures fell on Sunday night due to the new tariffs, raising concerns about inflation and global growth prospects, highlighting investor anxiety about the future economic landscape.
- Relative Strength in Asia-Pacific Markets: Despite tariff uncertainties, Asia-Pacific markets rose overnight, indicating regional resilience against Trump's policies, potentially linked to local economic fundamentals and investor confidence.
See More
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Daxor Corporation Milestone: Daxor Corporation celebrated the FDA 510(k) clearance of its next-generation, hand-held Blood Volume Analyzer (BVA) during a Nasdaq Closing Bell Ceremony on August 8, 2025.
Impact on Healthcare: The BVA technology aims to address the critical issue of accurately measuring blood volume, which can lead to improved patient outcomes and efficiencies in healthcare management, particularly for conditions like heart failure.
See More
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
Earnings Reports: Investors are receiving a variety of news on Thursday, particularly focused on earnings reports and other significant announcements in the stock market.
TipRanks Daily Wrap-Up: TipRanks provides a daily summary to help investors stay informed about the most important stock market headlines and developments.
See More
Daxor Corporation Reports 2025 Financial and Technological Advancements
- Strong Financial Performance: As of December 31, 2025, Daxor's net assets reached $45,887,266, reflecting a $10,094,965 increase from 2024, indicating robust growth potential in the blood volume measurement technology sector.
- Significant Revenue Growth: In 2025, Daxor's operating division reported a 45% increase in unaudited revenues year-over-year, primarily driven by sales of single-use blood volume diagnostic kits for heart failure management and military contracts, highlighting rapid market demand.
- FDA Approval of New Product: Daxor received FDA 510(k) clearance in August 2025 for its next-generation portable blood volume analyzer, which provides results three times faster than the previous system, significantly enhancing clinical fluid management efficiency.
- Strategic Restructuring and Enhanced Transparency: Daxor plans to transition its regulatory reporting framework from the Investment Company Act of 1940 back to the Securities Exchange Act of 1934, which is expected to simplify financial disclosures, boost investor confidence, and attract deeper institutional interest.
See More
Daxor Reports 45% Year-over-Year Revenue Growth
- Significant Revenue Growth: Daxor's unaudited operating revenues for FY 2025 increased by 45% year-over-year, indicating strong market demand and business expansion capabilities in the blood volume sector.
- Net Asset Value Increase: As of December 31, 2025, Daxor's total net assets reached $45,887,266, an increase of over $10 million from the prior year, reflecting effective asset management and enhanced investor confidence.
- Per-Share Value Growth: The net asset value per share rose to $9.07, representing a $1.82 increase compared to December 31, 2024, demonstrating the company's positive progress in enhancing shareholder value.
- Investment Activity Returns: Daxor recorded net realized gains of $745,334 from investment activities for the fiscal year and sold its remaining investment positions in December 2025 to focus entirely on its primary blood volume business, showcasing a strategic decision to concentrate resources.
See More
Geopolitical Crisis in the Middle East Impacts European Stocks
- Market Sentiment Decline: European stocks are expected to open lower due to the ongoing geopolitical crisis in the Middle East, with the UK's FTSE index projected to drop by 0.7%, Germany's DAX down 1%, France's CAC 40 down 0.75%, and Italy's FTSE MIB down 0.6%, reflecting investor concerns about market outlook.
- Oil Price Surge: Global crude oil prices surged on Monday amid fears that the escalating U.S.-Iran conflict could disrupt oil infrastructure and push fuel prices higher, thereby increasing inflationary risks and adding economic pressure.
- Increased Demand for Safe Havens: As uncertainty rises, demand for gold as a safe haven has surged, with global equities under pressure, particularly as U.S. futures and Asian markets fell on Tuesday, indicating a risk-averse sentiment among investors.
- Military Reinforcements and Uncertain Situation: The U.S. military is sending more forces to the region, with President Trump stating that the conflict could last four to five weeks but may extend longer, highlighting the complexity and uncertainty of the situation, while the EU calls for de-escalation and civilian protection.
See More
Trump's Global Tariff Policy Sparks Market Volatility
- Negative Market Reaction: European stocks are expected to open lower as Trump's announcement to raise global tariffs from 10% to 15% creates uncertainty, with the U.K.'s FTSE projected to drop 0.2%, Germany's DAX down 0.7%, France's CAC 40 down 0.4%, and Italy's FTSE MIB down 0.45%, indicating market unease.
- Tariff Policy Shift: Trump stated on social media that the new tariffs would be effective immediately and warned of potential additional levies, reflecting his hardline stance on trade policy, which could exacerbate global trade tensions.
- Increased Market Uncertainty: U.S. stock futures fell on Sunday night due to the new tariffs, raising concerns about inflation and global growth prospects, highlighting investor anxiety about the future economic landscape.
- Relative Strength in Asia-Pacific Markets: Despite tariff uncertainties, Asia-Pacific markets rose overnight, indicating regional resilience against Trump's policies, potentially linked to local economic fundamentals and investor confidence.
See More
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Daxor Corporation Milestone: Daxor Corporation celebrated the FDA 510(k) clearance of its next-generation, hand-held Blood Volume Analyzer (BVA) during a Nasdaq Closing Bell Ceremony on August 8, 2025.
Impact on Healthcare: The BVA technology aims to address the critical issue of accurately measuring blood volume, which can lead to improved patient outcomes and efficiencies in healthcare management, particularly for conditions like heart failure.
See More
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
Earnings Reports: Investors are receiving a variety of news on Thursday, particularly focused on earnings reports and other significant announcements in the stock market.
TipRanks Daily Wrap-Up: TipRanks provides a daily summary to help investors stay informed about the most important stock market headlines and developments.
See More
